03 July 2024 : Clinical Research
Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma
Jie Wang1ABCDEFG*, Ming Yang2CD, Sheng Chen2CEF, Hongbo Zhu1AB, Zhirong Zhang1CDDOI: 10.12659/MSM.943551
Med Sci Monit 2024; 30:e943551
Table 2 Correlation between CST1 and the clinicopathological factors.
| Characters | CST1 | P* | Effect size | |
|---|---|---|---|---|
| Low | High | |||
| Gender | ||||
| Male | 40 | 14 | 0.688 | 0.044 |
| Female | 21 | 9 | ||
| Age | ||||
| ≤60 | 46 | 16 | 0.589 | 0.059 |
| >60 | 15 | 7 | ||
| Tumor diameter (cm) | ||||
| ≤5 | 26 | 6 | 0.164 | 0.152 |
| >5 | 35 | 17 | ||
| Macroscopic type | ||||
| Ulcerative | 39 | 13 | 0.184 | |
| Polypoid | 7 | 6 | 0.242 | |
| Others | 15 | 4 | ||
| Lesion number | ||||
| Single | 50 | 18 | 0.700 | 0.042 |
| Multiple | 11 | 5 | ||
| Site | ||||
| Stomach | 35 | 12 | 0.668 | 0.047 |
| Intestine | 26 | 11 | ||
| Chemotherapy | ||||
| No | 31 | 9 | 0.477 | 0.104 |
| Yes | 30 | 14 | ||
| Serum LDH | ||||
| Normal | 43 | 11 | 0.053 | 0.211 |
| High | 18 | 12 | ||
| PS | ||||
| <2 | 55 | 18 | 0.149 | 0.157 |
| 2–4 | 6 | 5 | ||
| Luanguo stage | ||||
| I–II1 | 49 | 16 | 0.293 | 0.115 |
| II2–IV | 12 | 7 | ||
| IPI | ||||
| <3 | 59 | 18 | 0.007 | 0.298 |
| 3–5 | 2 | 5 | ||
| * chi-square test. LDH – lactate dehydrogenase; PS – performence status; IPI – International Prognostic Index; CST1 – Cystatin SN. | ||||